Brown Advisory
STLN

Brown Advisory’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Brown Advisory’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,674
Closed -$29.5K – 1285
2024
Q1 		$29.5K Hold
18,674
– – ﹤0.01% 1233
2023
Q4 		$38.1K Hold
18,674
– – ﹤0.01% 1205
2023
Q3 		$26.1K Hold
18,674
– – ﹤0.01% 1179
2023
Q2 		$10.3K Buy
+18,674
New +$9.88K ﹤0.01% 1175

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return
BFM
Boston Financial Management Boston, Massachusetts $3.31B AUM 19.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brown Advisory's STLN Position: Q2 2024 in Review

Brown Advisory sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q2 2024, closing a stake of 18,674 shares — an estimated $29.5K sold.

Brown Advisory first reported a position in STLN in Q2 2023 and held it in 4 quarters. The position peaked at $38.1K in Q4 2023. 39 funds tracked by Wall St. Rank hold STLN as of Q2 2024.

  • Brown Advisory reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Brown Advisory sold 18,674 Starling Oncology Institute, Inc. Common Stock shares in Q2 2024, an estimated $29.5K.
  • Brown Advisory first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2023 and held it in 4 quarters.
  • Brown Advisory's Starling Oncology Institute, Inc. Common Stock position peaked at $38.1K in Q4 2023.
  • 39 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2024.

Based on Brown Advisory's 13F filing for Q2 2024, filed 14 Aug 2024.